济川药业：全资子公司与康方生物、康融东方签署独占性商业化权益协议

Core Viewpoint - Jichuan Pharmaceutical (600566) has signed an exclusive commercialization rights agreement with Zhongshan Kangfang Biopharmaceutical Co., Ltd. and Kangrong Dongfang (Guangdong) Pharmaceutical Co., Ltd. for the drug Inusimab injection [1] Group 1 - Jichuan's wholly-owned subsidiary, Jichuan Pharmaceutical Group Co., Ltd., and Jiangsu Jiyuan Pharmaceutical Co., Ltd. are involved in the agreement with Kangfang [1] - The agreement grants Jichuan exclusive commercialization rights for Inusimab injection, which has been developed and approved for market by Kangfang [1] - Jichuan will pay a total of 80 million yuan (including tax) as a licensing fee and up to 10 million yuan (including tax) in milestone payments [1]